Recombinant Human IL-2 Protein，His

Interleukin-2 (IL-2) is a key cytokine that plays a crucial role in the immune response, particularly in the proliferation and activation of T cells. It was first discovered in the late 1970s and has since been recognized for its therapeutic potential in various diseases, including cancer and autoimmune disorders. Due to its significant role in immune regulation, research on recombinant IL-2 has gained momentum, especially in the context of immunotherapy. Recombinant DNA technology has enabled the production of high-purity IL-2 for both research and clinical applications. This has opened avenues for investigating its use as an adjuvant in cancer vaccination, enhancing the efficacy of anti-tumor responses by promoting T cell expansion and activity. Moreover, IL-2 has been utilized in combination therapies to synergize with other immune-modulating agents. However, its clinical use is limited by adverse effects such as vascular leak syndrome and dose-dependent toxicity. As a result, ongoing research aims to develop safer IL-2 variants, optimize dosing regimens, and explore novel delivery methods to maximize its therapeutic benefits while minimizing side effects. Investigations into the mechanisms of action of IL-2 at the cellular and molecular levels are also being conducted to better understand its role in immune responses. Overall, the study of recombinant IL-2 continues to be a significant area of interest, contributing to advancements in immunotherapy and the development of novel treatment strategies for cancer and other immune-related conditions.